TP53 and breast carcinoma: In another study, Chou et al. stated that 10 affected the regulation of tumor protein p53-related pathways in the tumor cell cycle by inducing endoplasmic reticulum (ER) stress, promoting p53 release, and inhibiting cyclin A, cyclin B, and cyclin dependent kinase-2 (CDK2) activities, thus causing the stagnation of MCF-7 breast cancer cells in the S phase [93].